Pfizer is moving forward with a promising once-daily version of their weight loss pill, danuglipron, after seeing positive results in early-stage studies. The company has identified a formulation with a favorable safety profile and plans to conduct further trials to determine the ideal dose. Pfizer aims to compete in the growing market for weight loss and diabetes drugs known as GLP-1 agonists, which could reach $100 billion by the end of the decade. Despite previous setbacks, including discontinuing a twice-daily version of danuglipron, Pfizer remains committed to developing effective obesity treatments. They are exploring partnerships and potential licensing deals while working to improve accessibility and supply of their drugs. Pfizer's continued efforts in this space signal their dedication to addressing the global obesity epidemic and providing innovative solutions for patients.